Skip to content

Forum Update: Supporting Community-Led Discussion

The forum was created as a space for shared learning and peer support, and as the community grows, we want to lean more fully into that purpose.

Going forward, PAAB will be taking a more listening-first role in forum discussions. Rather than responding immediately to every question, we’ll be encouraging members to engage with one another, share experiences, and help build collective understanding. PAAB will continue to monitor conversations and will step in to:

  • Correct any misunderstandings
  • Provide guidance when questions remain unanswered after a few days
  • Support discussions where official clarification is needed

Our goal is to foster a collaborative, trusted community where knowledge is shared and strengthened by everyone’s contributions.

Thank you for being part of the conversation.

  • Announcements regarding our community

    10 10
    10 Topics
    10 Posts
    D
    Did you know? In celebration of PAAB’s 50th Anniversary, Messenger is now free of charge with all new and ongoing ARO submissions until March 31, 2026. Help reduce rounds of revision by communicating with your reviewer via messenger before resubmission. Learn more about Messenger here. [image: 1769440840904-messenger-is-free-of-charge-on-all-aro-submissions.png] @Manufacturer @Agency
  • A place to talk about whatever you want

    15 43
    15 Topics
    43 Posts
    A
    Hi Adelaide - A 'Sell Sheet' is a broad term, that doesn't appear to be defined in Health Canada guidance documents. Advertising is classified by intent not format, and defined as anything with "the purpose of promoting the sale or disposal of a drug." So if you're referring to a Pharmacy Order/Info Sheet (containing SKUs or prices not contained in the TMA), while this is still advertising, it may be treated differently if limited to logistical information alone. s3.2.3.2 of the Health Canada Guidance states that any HCP material regarding opioid use is expected to undergo preclearance, where your specific content will be reviewed. PAAB offers Written Opinion services, and now Rapid Access Consults, which may help guide development of your specific material.
  • Got a question? Ask away!

    1 2
    1 Topics
    2 Posts
    Jennifer CarrollJ
    Hey @mhouzer The difference between the Standard 4-day initial review of RMTs and submitting as an ARO-4 is that the subsequent revision turnaround time will be an expedited 2-days rather than the standard 3-days. If you anticipate needing a few rounds of back and forth, this can be a good option to get to your final letter more quickly.
  • Blog posts from individual members

    5 5
    5 Topics
    5 Posts
    Jennifer CarrollJ
    Good Morning @Manufacturer and @Agency The PAAB Quarterly Tag and CEI Reports for 2025 have been updated to contain data for Q4. See the Tag report here and the CEI report here. This year is PAAB's 50th Anniversary! Stay tuned for treats throughout the year to celebrate this milestone. We're starting the celebration with: Client Messenger Service - Free with all ARO in Q1 to celebrate PAAB's 50th Anniversary Learn more here. Have a great weekend PAAB
  • Have questions about how to use the forum, set up your account, functionality etc.? Ask them here and we'll help you out.

    3 3
    3 Topics
    3 Posts
    D
    Lets start with a quick registration video.
  • Do you have questions about particular sections of the PAAB code? Do you have insights on how sections of the code be improved? Do you want to share insights about how related standards are addressed in other jurisdictions? Post here.

    89 205
    89 Topics
    205 Posts
    Jennifer CarrollJ
    Hello @Maha-Dogar Thanks for your question. Please note that this topic has been addressed previously. Searching “secondary endpoints” in the forum should provide the relevant guidance. Note that the response applies regardless of whether or not the study appears in the TMA.
  • 131 Topics
    231 Posts
    D
    Introducing NEW PAAB Consultation Services PAAB is pleased to introduce a set of enhanced consultation services designed to make it easier for clients to engage with us early and often throughout the development and review process. These services provide flexible, timely access to PAAB expertise, helping you anticipate issues, reduce rework, and move forward with confidence. Then and now? For some submissions, the traditional approach may have been seen as reactive, sequential (wait – revise – resubmit – wait again) and fragmented (changing copy in one location often impacts others). These offerings shift the experience to proactive, integrated and time-efficient at the client’s discretion. Rapid Access Consults “We need a quick, focused answer now so we don’t go down the wrong path” Rapid Access Consults offer fast-turnaround feedback from a team of two reviewers on targeted questions or materials. This service is designed for situations where speed is critical and focused regulatory insight is needed quickly. Click to see the fee schedule. Intra Review Consults “We want to fix issues or attack complex revisions before they turn into delays” Intra Review Consults allow clients to share screen with a team of two reviewers and problem-solve with PAAB while a submission or review is already underway. These consults help address questions, clarify expectations, and resolve issues before they escalate. Click to see the fee schedule. Product Monograph Consults “We want to build regulatory expectations into our plan” The Product Monograph has broad and significant implications for the is the basis for claims that can be made in drug advertising. Product Monograph consults support proactive project management by aligning regulatory considerations with your desired key advertising messages. This service helps teams integrate PAAB guidance into broader planning and execution and helps improve the predictability of timelines at launch. Click to see the fee schedule. In addition to these new services, keep in mind our other services to enhance collaboration with PAAB: Messenger “We want quick, binding feedback on pivotal segments of the APS prior to resubmission ” Messenger provides quick, informal access to your reviewer for clarification on specific questions. It’s ideal for early-stage thinking or minor issues where timely guidance can keep projects moving. Click to see the fee schedule. One-Hour Consults “We want to plan ahead and get detailed feedback on a key issue” One-hour consults provide a structured, in-depth discussion on defined topics. They are well suited for strategic questions, interpretation of guidance, or planning next steps. Click to see the fee schedule. Written Opinions “I would like written feedback on a key issue before implementing something across a campaign” Opinion submissions provide clear, written guidance on the acceptability of proposed pharmaceutical advertising and promotional materials. Through a timely, confidential review process, PAAB offers opinions to help stakeholders understand how specific concepts or executions may align with the PAAB Code, supporting compliance and reducing regulatory risk early in development. Click to see the fee schedule. Clarification Calls “I need some clarity on a review issue identified in my letter” Clarification calls are short, 10-15 minute clarification calls that happen within the context of a specific comment with your reviewer. These are included within the cost of the review and should be limited to one call per round of review. Clarification calls are used to clarify points in your review letter to help move the file forward and reduce rounds of revision. Escalation Calls “I need a final, binding ruling on a key review issue” PAAB escalation calls are calls with the Director of Preclearance Services intended to address review issues that have reached an impasse. Please note that escalation calls should only be requested after attempts have been made to resolve issues in writing and over the phone with the primary reviewer on the file. See section iii. General Questions “I have a quick question on general PAAB guidance” General questions are 5-minute, non-billable calls where reviewers can explain the meaning of existing PAAB guidance as it relates to general scenarios. Forum “I want to connect with industry peers and have discussions on PAAB topics” The forum was created as a space to build a community where members can learn from one another, share perspectives, and build a collective understanding through open discussion. As the community has grown, so has the depth of experience and insight within it. To better support that original intent, PAAB will be taking a more listening-first role in forum discussions. Rather than responding immediately to every question, we’ll be encouraging members to engage with one another, share their experiences, and help unpack questions together. This means you may notice more space for peer-to-peer conversation before PAAB weighs in. That’s intentional. Some of the most valuable insights come from real-world application and shared interpretation. PAAB believes this forum is uniquely positioned to surface that collective knowledge. PAAB will continue to actively monitor discussions and will step in to: Clarify or correct any misunderstandings Provide guidance where questions remain unanswered after a few days Support the conversation when official interpretation is needed Our goal is to grow a collaborative, trusted community where knowledge is shared, confidence is built, and learning is continuous. Leaning into collective knowledge supports the growth and development of the industry. Thank you for contributing your expertise, curiosity, and perspective. This forum is strongest when it reflects the voices and experiences of the community itself. Together, these services are designed to support ongoing dialogue with PAAB—helping clients engage earlier, consult more often, and navigate the review process more effectively. @Agency @Manufacturer
  • 1k Topics
    2k Posts
    Jennifer CarrollJ
    Hi there, While standard setting organizations (i.e. reputable patient associations) may be used to support information in Patient Information APS as noted in Code section 6, acknowledgement from a standard-setting organization is not sufficient as endorsement for guidelines as they are not considered a recognized, Canadian, authoritative, medical body. However, PAAB will consider recognized, authoritative US consensus guidelines (when deemed acceptable), in the absence of Canadian guidelines, without need for endorsement from a recognized, authoritative Canadian medical body. Please refer to the PAAB document “What constitutes current medical opinion?” for further details.
The responses, guidance, and advisories provided by the Pharmaceutical Advertising Advisory Board (PAAB), including but not limited to those available through the PAAB Forum, the PAAB website, and any PAAB correspondences, are specifically intended to assist individuals navigating the PAAB preclearance system. Repurposing or reproducing this content without written consent from the PAAB Commissioner is strictly prohibited. This prohibition includes, but is not limited to, use in machine learning or AI models.